Presentation (CTI)

OBJECTIVES: To evaluate the operational and methodological implications of “PICO multiplicity” in the inaugural European Union Joint Clinical Assessment (JCA), and to quantify alignment between Member State driven PICO requirements and the clinical evidence submitted by the Health Technology Developer (HTD).
METHODS: A structured case study analysis was conducted using the first EU JCA report for tovorafenib in paediatric low-grade glioma (published June 9, 2026). Consolidated PICO frameworks defined during the scoping phase were systematically extracted and mapped against the HTD's submission dossier. Evidence gaps were categorized by mismatch type (e.g., comparator, population, data availability), and their impact on indirect treatment comparison (ITC) feasibility and assessor evaluation was analysed.
RESULTS: The JCA Assessment Subgroup defined eight distinct consolidated PICO frameworks across three target patient subpopulations, reflecting highly fragmented national comparator preferences including diverse chemotherapy regimens and targeted BRAF inhibitors. Direct clinical evidence from the single-arm pivotal trial fully aligned with only one requested PICO (12.5%). The remaining seven requested PICOs (87.5%) demonstrated severe structural evidence gaps driven by the absence of direct comparative data within the trial dossier. These gaps forced a reliance on highly uncertain unanchored ITCs and external control arms, which were heavily critiqued by reviewers due to cross-trial heterogeneity, unmeasured confounding, and immature long-term outcomes.
CONCLUSIONS: The inaugural JCA demonstrates that "PICO multiplicity" is a major structural challenge under the EU HTAR, with 87.5% of requested frameworks lacking direct comparative trial evidence. This stark gap highlights a critical need for manufacturers to integrate multi-country comparator strategies early in global clinical trial design to mitigate evidence mismatches and ensure HTA viability in pan-European assessments.